Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity

Despite extensive efforts over 40 years, few effective KRAS inhibitors have been developed to date, mainly due to the undruggable features of KRAS proteins. In addition to the direct approach to KRAS via covalent inhibition, modulation of the prenyl-binding protein PDEδ that binds with farnesylated...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jungeun, Lee, Ho Jin, Lee, Yeongcheol, Lim, Bumhee, Gam, Jongsik, Oh, Dong-Chan, Lee, Jeeyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225715/
https://www.ncbi.nlm.nih.gov/pubmed/35695156
http://dx.doi.org/10.1080/14756366.2022.2086865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225715/
https://www.ncbi.nlm.nih.gov/pubmed/35695156
http://dx.doi.org/10.1080/14756366.2022.2086865

Ejemplares similares